• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Gains 75 Points; Acuity Brands Posts Upbeat Earnings

    4/3/24 2:30:25 PM ET
    $ABIO
    $AYI
    $CASA
    $KTRA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Building Products
    Consumer Discretionary
    Get the next $ABIO alert in real time by email

    U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 0.3% on Wednesday.

    The Dow traded up 0.08% to 39,200.08 while the NASDAQ rose 0.46% to 16,315.68. The S&P 500 also rose, gaining, 0.31% to 5,221.70.

    Check This Out: Insiders Buying Walgreens And 2 Other Stocks

     

    Leading and Lagging Sectors

     

    Industrials shares jumped by 0.8% on Wednesday.

    In trading on Wednesday, consumer staples shares fell by 0.9%.

     

    Top Headline

     

    Acuity Brands, Inc (NYSE:AYI) reported better-than-expected earnings for its second quarter.

    The company posted a quarterly net sales decline of 4.0% year-over-year to $905.9 million, missing the consensus of $907.7 million. It clocked an adjusted EPS of $3.38, beating the consensus of $3.25.

     

    Equities Trading UP

     

    Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares shot up 63% to $0.1637 after the company entered a merger agreement with TuHURA Biosciences.

    Shares of ARCA biopharma, Inc. (NASDAQ:ABIO) got a boost, surging 78% to $3.04 after the company and Oruka Therapeutics announced a merger agreement.

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were also up, gaining 32% to $5.17 after the company's Fanapt received FDA approval for the acute treatment of bipolar I disorder.

     

    Equities Trading DOWN

     

    Casa Systems, Inc. (NASDAQ:CASA) shares dropped 81% to $0.0485 after the Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court.

    Shares of View, Inc. (NASDAQ:VIEW) were down 63% to $0.4020 after the company filed for Chapter 11 bankruptcy. The company on Tuesday said it reached a real with Cantor Fitzgerald and RXR to become a private company.

    Sintx Technologies, Inc. (NASDAQ:SINT) was down, falling 46% to $0.0227 after the company announced pricing of a $1.5 million public offering of common stock.

    Also Check This Out: How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q1 Earnings Report

     

    Commodities

     

    In commodity news, oil traded up 0.5% to $85.61 while gold traded up 1.4% at $2,313.90.

    Silver traded up 4.1% to $26.995 on Wednesday, while copper rose 2.9% to $4.1865.

     

    Euro zone

     

    European shares closed higher today. The eurozone’s STOXX 600 rose 0.29%, London’s FTSE 100 rose 0.03% while Spain’s IBEX 35 Index rose 0.52% The German DAX rose 0.46% French CAC 40 rose 0.29% while Italy’s FTSE MIB Index rose 0.45%.

    The consumer price inflation rate in the eurozone eased to 2.4% year-over-year in March, compared to market expectations of 2.6%, while the unemployment rate in the eurozone came in at 6.5% in February, versus market estimates of 6.4%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Wednesday, with Japan’s Nikkei 225 falling 0.97%, Hong Kong’s Hang Seng Index dipping 1.22%, China’s Shanghai Composite Index falling 0.18% and India’s S&P BSE Sensex falling 0.1%.

    Retail sales in Hong Kong climbed 0.5% year-over-year in February following a 1.2% decline in the prior month. The Caixin China General Services PMI rose to 52.7 in March from 52.5 in February, while composite PMI rose to 52.7 in March from 52.5 in the previous two months.

    The au Jibun Bank Japan services PMI fell to 54.1 in March from a preliminary level 54.9, while composite PMI fell to 51.7 in March versus a flash reading of 52.3.

     

    Economics

     

    Mortgage applications in the U.S. declined by 0.6% on the week ending March 29, 2024.

    Private businesses in the U.S. added 184,000 workers in March compared to a revised 155,000 gain in February, and topping market estimates of 148,000.

    The S&P Global composite PMI was revised lower to 52.1 in March from a preliminary reading of 52.2.

    The ISM services PMI declined to 51.4 in March compared to February’s reading of 52.6 and compared to market estimates of 52.7.

    U.S. crude oil inventories increased by 3.21 million barrels in the week ended March 29, 2024, compared to market estimates of a 1.511 million decline, the EIA said.

    Now Read This: Top 5 Industrials Stocks That Could Blast Off This Quarter

    Get the next $ABIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABIO
    $AYI
    $CASA
    $KTRA

    CompanyDatePrice TargetRatingAnalyst
    SiNtx Technologies Inc.
    $SINT
    4/13/2026$10.00Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Acuity Inc.
    $AYI
    10/2/2025$330.00 → $390.00Buy
    TD Cowen
    Acuity Inc.
    $AYI
    9/2/2025$380.00Equal Weight → Overweight
    Wells Fargo
    Acuity Inc.
    $AYI
    1/14/2025$304.00 → $370.00Equal-Weight → Overweight
    Morgan Stanley
    Acuity Inc.
    $AYI
    1/6/2025$304.00Equal-Weight
    Morgan Stanley
    Acuity Inc.
    $AYI
    1/2/2025Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ABIO
    $AYI
    $CASA
    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Duncan Charles Cliff was granted 57,101 shares (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    4/24/26 4:36:42 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Duncan Charles Cliff

    3 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    4/24/26 4:35:12 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Elmore Robert Ryan

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    4/14/26 8:30:10 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

    WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan's appointment, Vanda's Board of Directors is now comprised of seven directors, six of whom are independent. Dr. Duncan is a highly experienced and respected leader in the life sciences and biotechnology sector," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are excited to welcome him to our strong and independent Boa

    4/22/26 5:13:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

    WASHINGTON, April 9, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification. The proposal would eliminate the simple statutory requirement that the FDA must review a new drug application (NDA) within 180 days of filing.In plain terms, this change would extend statutory review timelines rather than shorten them. It would replace the 180-day legal requirement with the longer Prescription Drug User Fee Act (PDUFA) and Generic Drug User Fee Amendments (GDUFA) per

    4/9/26 11:02:00 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

    WASHINGTON, April 8, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving glucagon-like peptide-1 (GLP-1) receptor agonist therapies. NEREUS™ was recently approved for the prevention of vomiting induced by motion.1 GLP-1 receptor agonists, including semaglutide and tirzepatide, have transformed the treatment of type 2 diabetes and obesity. However, gastrointestinal side effects, particularly nausea and vomiting, remain

    4/8/26 4:44:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $ABIO
    $AYI
    $CASA
    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ABIO
    $AYI
    $CASA
    $KTRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $ABIO
    $AYI
    $CASA
    $KTRA
    SEC Filings

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on SINTX Technologies with a new price target

    H.C. Wainwright initiated coverage of SINTX Technologies with a rating of Buy and set a new price target of $10.00

    4/13/26 9:01:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    B. Riley Securities initiated coverage on Vanda Pharma with a new price target

    B. Riley Securities initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $11.00

    11/5/25 7:30:12 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc.

    DEFA14A - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    4/23/26 4:50:50 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Vanda Pharmaceuticals Inc.

    DEF 14A - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    4/23/26 4:48:32 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    4/22/26 5:23:06 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Financials

    Live finance-specific insights

    View All

    Acuity Reports Fiscal 2026 Second-Quarter Results

    Strong Execution Delivers Sales Growth, Margin Expansion and EPS Improvement Delivered Net Sales of $1.1B, an Increase of 5% Compared to the Prior YearDelivered Operating Profit of $133M, Up 21% Compared to the Prior Year; Grew Adjusted Operating Profit to $176M, Up 8% Compared to the Prior YearDelivered Diluted EPS of $3.09, Up 26% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.14, Up 11% Compared to the Prior Year ATLANTA, April 02, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI), ("Acuity"), a market-leading industrial technology company, delivered net sales of $1.1 billion in the second quarter, ended February 28, 2026, an increase of $49.4 million, or 4.9 percent, comp

    4/2/26 6:00:00 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity Inc. Declares Quarterly Dividend

    Atlanta, March 26, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) will pay a quarterly dividend of 20 cents per share. The dividend is payable on May 1, 2026, to shareholders of record on April 17, 2026.   About Acuity  Acuity Inc. (NYSE:AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light and more things to come. Through our two business segments, Acuity Brands Lighting (ABL) and Acuity Intelligent Spaces (AIS), we design, manufacture, and bring to market products and services that make a valuable difference in people's lives. We achieve growth through the development of innovative new products and services, including lighting, l

    3/26/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    Acuity to Announce Fiscal 2026 Second-Quarter Results on April 2, 2026

    ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE:AYI) (the "Company") will release fiscal 2026 second-quarter results on Thursday, April 2, 2026 at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. Neil Ashe, Chief Executive Officer of Acuity Inc., will lead the call. The webcast, earnings release, and supplemental presentation can be accessed via the Investor Relations section of the Company's website at www.investors.acuityinc.com on Thursday, April 2, 2026. The online replay will remain available for a limited time following the call. A replay of the call will also be posted to the Investor Relations site two hours after the completion of the conference call and

    2/27/26 4:15:00 PM ET
    $AYI
    Building Products
    Consumer Discretionary

    $ABIO
    $AYI
    $CASA
    $KTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acuity Brands Inc.

    SC 13G/A - ACUITY BRANDS INC (0001144215) (Subject)

    11/12/24 9:50:12 AM ET
    $AYI
    Building Products
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by ARCA biopharma Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    9/13/24 4:57:00 PM ET
    $ABIO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ABIO
    $AYI
    $CASA
    $KTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

    WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 2026. Following Dr. Duncan's appointment, Vanda's Board of Directors is now comprised of seven directors, six of whom are independent. Dr. Duncan is a highly experienced and respected leader in the life sciences and biotechnology sector," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are excited to welcome him to our strong and independent Boa

    4/22/26 5:13:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care